This content is from: Features

How Dura will curb US securities class actions

Defence lawyers have hailed the Supreme Court's ruling in Dura Pharmaceuticals for restricting securities fraud litigation. William Sullivan and Tracey DeLange, counsel to Dura, argue that the ruling is also good for the economy

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an IFLR subscriber? Login here

Instant access to all of our content. Membership Options | One Week Trial